GrippeEspagneV1, Main, Exploration, bibRecord, 000270

DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Identifieur interne : 000270 ( Main/Exploration ); précédent : 000269; suivant : 000271

DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Auteurs : Gunnveig Grodeland [Norvège] ; Siri Mjaaland ; Kenneth H. Roux ; Agnete Brunsvik Fredriksen ; Bjarne Bogen

Source :

Journal of immunology (Baltimore, Md. : 1950) [ 1550-6606 ] ; 2013.

RBID : pubmed:23956431

Descripteurs français

KwdFr :
- Animaux (MeSH), Anticorps antiviraux (immunologie), Antigènes d'histocompatibilité de classe II (immunologie), Cytométrie en flux (MeSH), Espagne (épidémiologie), Hémagglutinines (immunologie), Infections à Orthomyxoviridae (immunologie), Infections à Orthomyxoviridae (prévention et contrôle), Pandémies (MeSH), RT-PCR (MeSH), Souris (MeSH), Souris de lignée BALB C (MeSH), Souris de lignée C57BL (MeSH), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (immunologie), Technique de Western (MeSH), Test ELISA (MeSH), Transfection (MeSH), Vaccins antigrippaux (immunologie), Vaccins à ADN (immunologie).
MESH :
- génétique : Sous-type H1N1 du virus de la grippe A.
- immunologie : Anticorps antiviraux, Antigènes d'histocompatibilité de classe II, Hémagglutinines, Infections à Orthomyxoviridae, Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux, Vaccins à ADN.
- prévention et contrôle : Infections à Orthomyxoviridae.
- épidémiologie : Espagne.
- Animaux, Cytométrie en flux, Pandémies, RT-PCR, Souris, Souris de lignée BALB C, Souris de lignée C57BL, Technique de Western, Test ELISA, Transfection.
Wicri :
- geographic : Espagne.

English descriptors

KwdEn :
- Animals (MeSH), Antibodies, Viral (immunology), Blotting, Western (MeSH), Enzyme-Linked Immunosorbent Assay (MeSH), Flow Cytometry (MeSH), Hemagglutinins (immunology), Histocompatibility Antigens Class II (immunology), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (immunology), Mice (MeSH), Mice, Inbred BALB C (MeSH), Mice, Inbred C57BL (MeSH), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Pandemics (MeSH), Reverse Transcriptase Polymerase Chain Reaction (MeSH), Spain (epidemiology), Transfection (MeSH), Vaccines, DNA (immunology).
MESH :
- chemical , immunology : Antibodies, Viral, Hemagglutinins, Histocompatibility Antigens Class II, Influenza Vaccines, Vaccines, DNA.
- geographic , epidemiology : Spain.
- genetics : Influenza A Virus, H1N1 Subtype.
- immunology : Influenza A Virus, H1N1 Subtype, Orthomyxoviridae Infections.
- prevention & control : Orthomyxoviridae Infections.
- Animals, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Pandemics, Reverse Transcriptase Polymerase Chain Reaction, Transfection.

Abstract

New influenza A viruses with pandemic potential periodically emerge due to viral genomic reassortment. In the face of pandemic threats, production of conventional egg-based vaccines is time consuming and of limited capacity. We have developed in this study a novel DNA vaccine in which viral hemagglutinin (HA) is bivalently targeted to MHC class II (MHC II) molecules on APCs. Following DNA vaccination, transfected cells secreted vaccine proteins that bound MHC II on APCs and initiated adaptive immune responses. A single DNA immunization induced within 8 d protective levels of strain-specific Abs and also cross-reactive T cells. During the Mexican flu pandemic, a targeted DNA vaccine (HA from A/California/07/2009) was generated within 3 wk after the HA sequences were published online. These results suggest that MHC II-targeted DNA vaccines could play a role in situations of pandemic threats. The vaccine principle should be extendable to other infectious diseases.

DOI: 10.4049/jimmunol.1300504
PubMed: 23956431
PubMed Central: PMC3767367

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 00233
to stream Main, to step Curation: 000233

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.</title>
<author><name sortKey="Grodeland, Gunnveig" sort="Grodeland, Gunnveig" uniqKey="Grodeland G" first="Gunnveig" last="Grodeland">Gunnveig Grodeland</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo 0027, Norway. gunnveig.grodeland@medisin.uio.no</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo 0027</wicri:regionArea>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mjaaland, Siri" sort="Mjaaland, Siri" uniqKey="Mjaaland S" first="Siri" last="Mjaaland">Siri Mjaaland</name>
</author>
<author><name sortKey="Roux, Kenneth H" sort="Roux, Kenneth H" uniqKey="Roux K" first="Kenneth H" last="Roux">Kenneth H. Roux</name>
</author>
<author><name sortKey="Fredriksen, Agnete Brunsvik" sort="Fredriksen, Agnete Brunsvik" uniqKey="Fredriksen A" first="Agnete Brunsvik" last="Fredriksen">Agnete Brunsvik Fredriksen</name>
</author>
<author><name sortKey="Bogen, Bjarne" sort="Bogen, Bjarne" uniqKey="Bogen B" first="Bjarne" last="Bogen">Bjarne Bogen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23956431</idno>
<idno type="pmid">23956431</idno>
<idno type="doi">10.4049/jimmunol.1300504</idno>
<idno type="pmc">PMC3767367</idno>
<idno type="wicri:Area/Main/Corpus">00233</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00233</idno>
<idno type="wicri:Area/Main/Curation">000233</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000233</idno>
<idno type="wicri:Area/Main/Exploration">000233</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.</title>
<author><name sortKey="Grodeland, Gunnveig" sort="Grodeland, Gunnveig" uniqKey="Grodeland G" first="Gunnveig" last="Grodeland">Gunnveig Grodeland</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo 0027, Norway. gunnveig.grodeland@medisin.uio.no</nlm:affiliation>
<country xml:lang="fr">Norvège</country>
<wicri:regionArea>Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo 0027</wicri:regionArea>
<placeName><settlement type="city">Oslo</settlement>
<region nuts="2">Østlandet</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mjaaland, Siri" sort="Mjaaland, Siri" uniqKey="Mjaaland S" first="Siri" last="Mjaaland">Siri Mjaaland</name>
</author>
<author><name sortKey="Roux, Kenneth H" sort="Roux, Kenneth H" uniqKey="Roux K" first="Kenneth H" last="Roux">Kenneth H. Roux</name>
</author>
<author><name sortKey="Fredriksen, Agnete Brunsvik" sort="Fredriksen, Agnete Brunsvik" uniqKey="Fredriksen A" first="Agnete Brunsvik" last="Fredriksen">Agnete Brunsvik Fredriksen</name>
</author>
<author><name sortKey="Bogen, Bjarne" sort="Bogen, Bjarne" uniqKey="Bogen B" first="Bjarne" last="Bogen">Bjarne Bogen</name>
</author>
</analytic>
<series><title level="j">Journal of immunology (Baltimore, Md. : 1950)</title>
<idno type="eISSN">1550-6606</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Blotting, Western (MeSH)</term>
<term>Enzyme-Linked Immunosorbent Assay (MeSH)</term>
<term>Flow Cytometry (MeSH)</term>
<term>Hemagglutinins (immunology)</term>
<term>Histocompatibility Antigens Class II (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Mice (MeSH)</term>
<term>Mice, Inbred BALB C (MeSH)</term>
<term>Mice, Inbred C57BL (MeSH)</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Pandemics (MeSH)</term>
<term>Reverse Transcriptase Polymerase Chain Reaction (MeSH)</term>
<term>Spain (epidemiology)</term>
<term>Transfection (MeSH)</term>
<term>Vaccines, DNA (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Antigènes d'histocompatibilité de classe II (immunologie)</term>
<term>Cytométrie en flux (MeSH)</term>
<term>Espagne (épidémiologie)</term>
<term>Hémagglutinines (immunologie)</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Infections à Orthomyxoviridae (prévention et contrôle)</term>
<term>Pandémies (MeSH)</term>
<term>RT-PCR (MeSH)</term>
<term>Souris (MeSH)</term>
<term>Souris de lignée BALB C (MeSH)</term>
<term>Souris de lignée C57BL (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Technique de Western (MeSH)</term>
<term>Test ELISA (MeSH)</term>
<term>Transfection (MeSH)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins à ADN (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Hemagglutinins</term>
<term>Histocompatibility Antigens Class II</term>
<term>Influenza Vaccines</term>
<term>Vaccines, DNA</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Antigènes d'histocompatibilité de classe II</term>
<term>Hémagglutinines</term>
<term>Infections à Orthomyxoviridae</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Blotting, Western</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Flow Cytometry</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Inbred C57BL</term>
<term>Pandemics</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>Transfection</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cytométrie en flux</term>
<term>Pandémies</term>
<term>RT-PCR</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris de lignée C57BL</term>
<term>Technique de Western</term>
<term>Test ELISA</term>
<term>Transfection</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">New influenza A viruses with pandemic potential periodically emerge due to viral genomic reassortment. In the face of pandemic threats, production of conventional egg-based vaccines is time consuming and of limited capacity. We have developed in this study a novel DNA vaccine in which viral hemagglutinin (HA) is bivalently targeted to MHC class II (MHC II) molecules on APCs. Following DNA vaccination, transfected cells secreted vaccine proteins that bound MHC II on APCs and initiated adaptive immune responses. A single DNA immunization induced within 8 d protective levels of strain-specific Abs and also cross-reactive T cells. During the Mexican flu pandemic, a targeted DNA vaccine (HA from A/California/07/2009) was generated within 3 wk after the HA sequences were published online. These results suggest that MHC II-targeted DNA vaccines could play a role in situations of pandemic threats. The vaccine principle should be extendable to other infectious diseases. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23956431</PMID>
<DateCompleted><Year>2013</Year>
<Month>11</Month>
<Day>13</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-6606</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>191</Volume>
<Issue>6</Issue>
<PubDate><Year>2013</Year>
<Month>Sep</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
<ISOAbbreviation>J. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.</ArticleTitle>
<Pagination><MedlinePgn>3221-31</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4049/jimmunol.1300504</ELocationID>
<Abstract><AbstractText>New influenza A viruses with pandemic potential periodically emerge due to viral genomic reassortment. In the face of pandemic threats, production of conventional egg-based vaccines is time consuming and of limited capacity. We have developed in this study a novel DNA vaccine in which viral hemagglutinin (HA) is bivalently targeted to MHC class II (MHC II) molecules on APCs. Following DNA vaccination, transfected cells secreted vaccine proteins that bound MHC II on APCs and initiated adaptive immune responses. A single DNA immunization induced within 8 d protective levels of strain-specific Abs and also cross-reactive T cells. During the Mexican flu pandemic, a targeted DNA vaccine (HA from A/California/07/2009) was generated within 3 wk after the HA sequences were published online. These results suggest that MHC II-targeted DNA vaccines could play a role in situations of pandemic threats. The vaccine principle should be extendable to other infectious diseases. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grodeland</LastName>
<ForeName>Gunnveig</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Oslo 0027, Norway. gunnveig.grodeland@medisin.uio.no</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mjaaland</LastName>
<ForeName>Siri</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Roux</LastName>
<ForeName>Kenneth H</ForeName>
<Initials>KH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fredriksen</LastName>
<ForeName>Agnete Brunsvik</ForeName>
<Initials>AB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bogen</LastName>
<ForeName>Bjarne</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>08</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Immunol</MedlineTA>
<NlmUniqueID>2985117R</NlmUniqueID>
<ISSNLinking>0022-1767</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006388">Hemagglutinins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000949">Histocompatibility Antigens Class II</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006388" MajorTopicYN="N">Hemagglutinins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000949" MajorTopicYN="N">Histocompatibility Antigens Class II</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>8</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>8</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23956431</ArticleId>
<ArticleId IdType="pii">jimmunol.1300504</ArticleId>
<ArticleId IdType="doi">10.4049/jimmunol.1300504</ArticleId>
<ArticleId IdType="pmc">PMC3767367</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Exp Med. 1983 Feb 1;157(2):687-704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6600489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2012 Jun;86(12):6970-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22496212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(1):e8617</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20111582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1990 Dec 1;145(11):3594-600</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2246504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2011 Apr;54(4):293-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21416231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2006 Dec 15;177(12):8410-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17142738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods. 1996 Oct;10(2):247-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8812677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2006 Nov 7;114(19):2056-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17060376</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Biol. 1988 Mar;106(3):629-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3279048</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 1999 Mar;17(3):253-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10096292</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1995 Apr;69(4):2357-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7533857</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1983 Aug 1;158(2):294-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6224879</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 1990 Jul;20(7):1457-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2117535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1993 Nov 15;151(10):5115-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8228213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomed Biotechnol. 2010;2010:174378</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20368780</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 1994 Jun;24(6):1262-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8206087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2009 Jul;45(3):174-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19540156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2007 Sep 15;110(6):1797-805</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17540847</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(7):e11580</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20657846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2006 Feb 3;355(5):1143-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16343533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Biol. 1986 Oct;103(4):1179-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2429970</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 1998 Sep;16(9):867-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9743122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1986 Jan;136(1):58-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3079611</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009;4(9):e7226</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19789652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2010;7:363</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21134292</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 1997 May 12;204(1):77-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9202712</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2006 Apr;13(4):776-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16414309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2012 Aug;25(4):297-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22816869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2008 Oct 15;112(8):3264-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18669894</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(6):e39075</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22720032</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2011;18(35):5466-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22087838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 1989;178:130-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2601621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1984 Jul;81(14):4515-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6431408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2001 May 24;411(6836):489-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11373683</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1993;11(10):994-1002</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8212832</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2007 Dec 15;196(12):1732-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18190252</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2011 Jan;85(1):448-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20980523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2007 Oct;6(5):659-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17931147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2012 Jul;20(7):1472-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22508490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Genet. 2008 Oct;9(10):776-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18781156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2012 Sep 1;189(5):2645-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22865916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Mar 1;25(11):2064-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17239494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Biotechnol. 1999 Jul;17(7):670-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10404160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2007 Apr 1;178(7):4169-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17371973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2011 Feb;24(1):45-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21319978</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1987 May 7-13;327(6117):59-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3472080</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(5):e63039</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23658796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1995 Jul;13(10):901-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7483762</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 2009;333:431-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19768418</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 1994 Apr;1(1):73-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7889402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2003 Sep 15;102(6):2130-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12775570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2009 Feb 18;27(8):1248-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19118593</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 Nov 1;25(44):7649-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17913307</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1985 Sep;82(17):5885-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3875853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2011 Aug;10(8):1183-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21854311</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2006 Feb;13(2):320-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16185933</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1987 Sep 1;139(5):1609-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2957430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hyg (Lond). 1972 Dec;70(4):767-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4509641</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Ther. 2009 Sep;17(9):1637-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19532140</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1988 Jan 15;140(2):404-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2447176</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunol. 2002 Sep;14(9):1027-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12202400</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1998 Nov;72(11):9404-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9765498</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Norvège</li>
</country>
<region><li>Østlandet</li>
</region>
<settlement><li>Oslo</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bogen, Bjarne" sort="Bogen, Bjarne" uniqKey="Bogen B" first="Bjarne" last="Bogen">Bjarne Bogen</name>
<name sortKey="Fredriksen, Agnete Brunsvik" sort="Fredriksen, Agnete Brunsvik" uniqKey="Fredriksen A" first="Agnete Brunsvik" last="Fredriksen">Agnete Brunsvik Fredriksen</name>
<name sortKey="Mjaaland, Siri" sort="Mjaaland, Siri" uniqKey="Mjaaland S" first="Siri" last="Mjaaland">Siri Mjaaland</name>
<name sortKey="Roux, Kenneth H" sort="Roux, Kenneth H" uniqKey="Roux K" first="Kenneth H" last="Roux">Kenneth H. Roux</name>
</noCountry>
<country name="Norvège"><region name="Østlandet"><name sortKey="Grodeland, Gunnveig" sort="Grodeland, Gunnveig" uniqKey="Grodeland G" first="Gunnveig" last="Grodeland">Gunnveig Grodeland</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000270 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000270 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeEspagneV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23956431
   |texte=   DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23956431" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeEspagneV1

This area was generated with Dilib version V0.6.37.
Data generation: Fri Sep 25 11:01:38 2020. Site generation: Sat Feb 13 17:38:04 2021

	Serveur d'exploration sur la grippe en Espagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Espagne

DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki